CRDF has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
CRDF has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cardiff Oncology's enterprise value is $121.67 Mil. Cardiff Oncology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-45.01 Mil. Therefore, Cardiff Oncology's EV-to-EBITDA for today is -2.70.
The historical rank and industry rank for Cardiff Oncology's EV-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest EV-to-EBITDA of Cardiff Oncology was 2.08. The lowest was -29.52. And the median was -1.19.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-04-19), Cardiff Oncology's stock price is $4.332. Cardiff Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.930. Therefore, Cardiff Oncology's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Cardiff Oncology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cardiff Oncology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Cardiff Oncology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cardiff Oncology's EV-to-EBITDA falls into.
Cardiff Oncology's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 121.672 | / | -45.014 | |
= | -2.70 |
Cardiff Oncology's current Enterprise Value is $121.67 Mil.
Cardiff Oncology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-45.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiff Oncology (NAS:CRDF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Cardiff Oncology's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 4.332 | / | -0.930 | |
= | At Loss |
Cardiff Oncology's share price for today is $4.332.
Cardiff Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.930.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Cardiff Oncology's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Gary W Pace | director | C/O RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857 |
Fairooz Kabbinavar | officer: Chief Medical Officer | C/O TOCAGEN INC., 4242 CAMPUS POINT COURT, STE. 500, SAN DIEGO CA 92121 |
Mark Erlander | officer: Chief Scientific Officer | C/O TROVAGENE, INC., 11055 FLINTKOTE AVENUE, SUITE A, SAN DIEGO CA 92121 |
Lale White | director | 310 GODDARD, SUITE 150, IRVINE CA 92618 |
James O Armitage | director | C/O TESARO, INC., 1000 WINTER ST., SUITE 3300, WALTHAM MA 02451 |
James E. Levine | officer: Chief Financial Officer | 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142 |
Renee P Tannenbaum | director | 9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054 |
Tod Smeal | officer: Chief Scientific Officer | 11055 FLINTKOTE AVENUE, SA DIEGO CA 92121 |
Katherine L Ruffner | officer: Chief Medical Officer | 11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121 |
Mani Mohindru | director | C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902 |
Rodney S Markin | director | C/O UNIVERSITY OF NEBR MEDICAL CENTER, 983135 NEBRASKA MEDICAL CENTER, OMAHA NE 68198-3135 |
Gary S Jacob | director | |
Vicki Kelemen | officer: Exec. VP and COO | 11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121 |
John P Brancaccio | director | C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852 |
Rajeev M. Shah | 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
From GuruFocus
By PRNewswire PRNewswire • 06-05-2023
By PRNewswire • 09-05-2023
By PRNewswire PRNewswire • 08-04-2022
By PRNewswire PRNewswire • 07-06-2022
By PRNewswire • 06-21-2023
By PRNewswire PRNewswire • 11-08-2022
By PRNewswire • 07-24-2023
By PRNewswire PRNewswire • 06-20-2023
By PRNewswire PRNewswire • 07-15-2022
By PRNewswire • 10-26-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.